Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis

B. Chaitanya, Keerthilatha M. Pai, Prahlad H. Yathiraj, Donald Fernandes, Yogesh Chhaparwal

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background & objectives Oral mucositis is inflammation of mucosa of oral cavity which is an inevitable and acute side effect in patients undergoing chemoradiotherapy for head & neck cancer. Though many agents have been tried in prevention & treatment of oral mucositis, until date no single agent exists that is universally established to be effective. Methods 60 Patients diagnosed with Head & Neck cancer recruited for concurrent chemo-radiotherapy were assigned in a double blind fashion into 2 groups using computer based 1:1 ratio randomization. Subjects in Group 1 were given Rebamipide gargle while subjects in Group 2 were given Placebo gargle in similar colour coded bottles to gargle 6 times/day. Subjective assessment of oral mucositis was done by Numeric Rating Scale (NRS) and objective scoring according to RTOG system. Results All subjects in the Group 1 reported good treatment compliance but 4 subjects in Group 2 developed burning sensation to gargle and were excluded. Onset of oral mucositis was 3.5 days earlier in Group 2 (mean = 11.17) as compared to Group 1 (mean = 14.63). At the end of chemo-radiotherapy, severity of oral mucositis was significantly lower in Group 1 (mean = 1.97) than in Group 2 (mean = 2.81). Interpretation & conclusion Findings of this study revealed that Rebamipide gargle may be an effective means to prolong the onset of oral mucositis and may reduce the severity of oral mucositis in undergoing chemo-radiotherapy.

Original languageEnglish
Pages (from-to)179-182
Number of pages4
JournalOral Oncology
Volume72
DOIs
Publication statusPublished - 01-09-2017

Fingerprint

Stomatitis
Radiotherapy
Head and Neck Neoplasms
Head
Chemoradiotherapy
Random Allocation
rebamipide
Mouth
Mucous Membrane
Color
Placebos
Inflammation
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

@article{739aaac0b5c44eec867cc29980bf9e8d,
title = "Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis",
abstract = "Background & objectives Oral mucositis is inflammation of mucosa of oral cavity which is an inevitable and acute side effect in patients undergoing chemoradiotherapy for head & neck cancer. Though many agents have been tried in prevention & treatment of oral mucositis, until date no single agent exists that is universally established to be effective. Methods 60 Patients diagnosed with Head & Neck cancer recruited for concurrent chemo-radiotherapy were assigned in a double blind fashion into 2 groups using computer based 1:1 ratio randomization. Subjects in Group 1 were given Rebamipide gargle while subjects in Group 2 were given Placebo gargle in similar colour coded bottles to gargle 6 times/day. Subjective assessment of oral mucositis was done by Numeric Rating Scale (NRS) and objective scoring according to RTOG system. Results All subjects in the Group 1 reported good treatment compliance but 4 subjects in Group 2 developed burning sensation to gargle and were excluded. Onset of oral mucositis was 3.5 days earlier in Group 2 (mean = 11.17) as compared to Group 1 (mean = 14.63). At the end of chemo-radiotherapy, severity of oral mucositis was significantly lower in Group 1 (mean = 1.97) than in Group 2 (mean = 2.81). Interpretation & conclusion Findings of this study revealed that Rebamipide gargle may be an effective means to prolong the onset of oral mucositis and may reduce the severity of oral mucositis in undergoing chemo-radiotherapy.",
author = "B. Chaitanya and Pai, {Keerthilatha M.} and Yathiraj, {Prahlad H.} and Donald Fernandes and Yogesh Chhaparwal",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.oraloncology.2017.07.024",
language = "English",
volume = "72",
pages = "179--182",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis. / Chaitanya, B.; Pai, Keerthilatha M.; Yathiraj, Prahlad H.; Fernandes, Donald; Chhaparwal, Yogesh.

In: Oral Oncology, Vol. 72, 01.09.2017, p. 179-182.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis

AU - Chaitanya, B.

AU - Pai, Keerthilatha M.

AU - Yathiraj, Prahlad H.

AU - Fernandes, Donald

AU - Chhaparwal, Yogesh

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background & objectives Oral mucositis is inflammation of mucosa of oral cavity which is an inevitable and acute side effect in patients undergoing chemoradiotherapy for head & neck cancer. Though many agents have been tried in prevention & treatment of oral mucositis, until date no single agent exists that is universally established to be effective. Methods 60 Patients diagnosed with Head & Neck cancer recruited for concurrent chemo-radiotherapy were assigned in a double blind fashion into 2 groups using computer based 1:1 ratio randomization. Subjects in Group 1 were given Rebamipide gargle while subjects in Group 2 were given Placebo gargle in similar colour coded bottles to gargle 6 times/day. Subjective assessment of oral mucositis was done by Numeric Rating Scale (NRS) and objective scoring according to RTOG system. Results All subjects in the Group 1 reported good treatment compliance but 4 subjects in Group 2 developed burning sensation to gargle and were excluded. Onset of oral mucositis was 3.5 days earlier in Group 2 (mean = 11.17) as compared to Group 1 (mean = 14.63). At the end of chemo-radiotherapy, severity of oral mucositis was significantly lower in Group 1 (mean = 1.97) than in Group 2 (mean = 2.81). Interpretation & conclusion Findings of this study revealed that Rebamipide gargle may be an effective means to prolong the onset of oral mucositis and may reduce the severity of oral mucositis in undergoing chemo-radiotherapy.

AB - Background & objectives Oral mucositis is inflammation of mucosa of oral cavity which is an inevitable and acute side effect in patients undergoing chemoradiotherapy for head & neck cancer. Though many agents have been tried in prevention & treatment of oral mucositis, until date no single agent exists that is universally established to be effective. Methods 60 Patients diagnosed with Head & Neck cancer recruited for concurrent chemo-radiotherapy were assigned in a double blind fashion into 2 groups using computer based 1:1 ratio randomization. Subjects in Group 1 were given Rebamipide gargle while subjects in Group 2 were given Placebo gargle in similar colour coded bottles to gargle 6 times/day. Subjective assessment of oral mucositis was done by Numeric Rating Scale (NRS) and objective scoring according to RTOG system. Results All subjects in the Group 1 reported good treatment compliance but 4 subjects in Group 2 developed burning sensation to gargle and were excluded. Onset of oral mucositis was 3.5 days earlier in Group 2 (mean = 11.17) as compared to Group 1 (mean = 14.63). At the end of chemo-radiotherapy, severity of oral mucositis was significantly lower in Group 1 (mean = 1.97) than in Group 2 (mean = 2.81). Interpretation & conclusion Findings of this study revealed that Rebamipide gargle may be an effective means to prolong the onset of oral mucositis and may reduce the severity of oral mucositis in undergoing chemo-radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85026361633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026361633&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2017.07.024

DO - 10.1016/j.oraloncology.2017.07.024

M3 - Article

AN - SCOPUS:85026361633

VL - 72

SP - 179

EP - 182

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -